COMP <GO>
CGON vs IMVT // 10Y YIELD & FRED MACRO BETA
CG Oncology Inc. (NASDAQ) VS. Immunovant Inc. (NASDAQ) • 15-METRIC TALLY: CGON 7
— IMVT 2
▲ 10Y YIELD & FRED MACRO BETA LEADER: CGON
LAST: $64.06 (+3.39%) • MKT CAP: $5.49B
macro-sensitivity
1.07
LAST: $29.04 (+2.22%) • MKT CAP: $5.87B
macro-sensitivity
0.98
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CGON VS. IMVT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CGON | IMVT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -20.80% | -35.00% | +14.20 | CGON | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.35% | -6.65% | +4.30 | CGON | /fcf-yield <GO> |
| Operating Margin | -12.10% | -36.00% | +23.90 | CGON | /operating-margins <GO> |
| Net Profit Margin | -10.20% | -29.50% | +19.30 | CGON | /net-margins <GO> |
| Revenue Growth (YoY) | 8.80% | 9.90% | -1.10 | IMVT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 26.00 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 5/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.5 | 36.4 | +5.10 | CGON | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.07 | 0.98 | +0.09 | CGON | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.0x | 36.0x | -16.00 | CGON | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.49B | $5.87B | -$376.0M | IMVT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CGON REV | IMVT REV | CGON GROSS % | IMVT GROSS % | CGON FCF | IMVT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $534.2M | $1.67B | — | — | -$132.5M | -$407.3M |
| FY 2024 | $321.1M | $1.37B | — | — | -$78.9M | -$376.6M |
| FY 2023 | $155.3M | $856.8M | — | — | -$45.7M | -$214.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CGON // BETA 1.07
IMVT // BETA 0.98